**AI-Enhanced Applications Design to**
**Improve Pharmaceutical Financial Management Accuracy & Efficiency (PFAE)**
*GxP Aware, Audit-Ready, Value-Driven*

Tara L. Mezzanotte & Dr. Scott M. Martin
Inventors, Architects
February 23nd, 2026

---

An international quarterly or yearly pharmaceutical financial plan goes far beyond embedded projections and forecasts, it represents a compound strategic framework that is built on meticulous forecasting, careful and disciplined budget management, all within an ever-changing precarious government regulated landscape. This often requires continuous recalculations that impacts performance that then converts financial data into tangible management decisions.

Pharmaceutical financial management is a combination of art, science, and mathematics, whereby one or two projection errors in R&D Financial Management, Manufacturing and Operations, Regulatory & Compliance Finance, Revenue Lifecycle & Patent Strategy Finance, or Risk Management could result in massive financial losses.

Pharmaceutical Financial Management is overdue to embrace human-gated, fully auditable, traceable, and explainable artificial intelligence to help assist with cost-benefit analysis, portfolio administration, pre-clinical and clinical process management, predict risk, and identify financial costs and billing anomalies.

The AI-Enhanced Applications Design to Improve Pharmaceutical Financial Management Accuracy & Efficiency (PFAE) has been specifically designed to fully provide regulatory and audit-ready support whereby inputs are traceable, drivers are explainable, and variances in financial models are quantified. In additional, PFAE also provides financial modeling probabilistic and prediction forecasting for manufacturing, clinical trials, regulatory financial management, and GTN.

PFAE is not deployed to make financial decisions, it is deployed to identify risk, quantify uncertainty, and justify variances with full human accountability and audit traceability.

---

## PFAE AGENTIC MODELS OVERVIEW:

### PFAE are 'Regulatory Safety First' Agents that Use Hard Constraints and (Human) Gating.

Hard Constraints:

Regulatory & Data Integrity Guardrails:

SOX, GxP, 21 CFR Part 11, data integrity =

ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available)

All model outputs are required to be:
Logged (immutable audit trail)
Versioned (model + data + prompts)
Reproducible (deterministic replays for audits)

$$\max_{\theta} \text{Utility}(\theta) \text{ s.t. } \begin{array}{l} g_{reg}(\theta) \le 0 \\ g_{audit}(\theta) \le 0 \\ g_{data\_integrity}(\theta) \le 0 \end{array}$$

AI agents support decisions, but humans approve all material outcomes
No 'silent' execution for regulated actions

---

**PFAE Agents are Traceable and Explainable**

Models must justify outputs (pricing, accruals, forecasts)
Deterministic fallbacks when confidence is low

*Design principles*
Models must justify outputs:
Pricing
Accruals
Forecasts

*Explainability artifacts are always considered primary outputs:*
Feature attributions
Rule traces
Scenario deltas

Deterministic fallback
If confidence < threshold:
Switch to rules engine/formula-based model
Force human review

Mathematical Framework that is technically a hybrid design whereby ML is used for quickness and deterministic logic for safety :

$$\text{Deploy}(y) = \begin{cases} y_{\text{model}}, & \text{if confidence}(y) \ge \tau \\ y_{\text{rule\_based,I}} & \text{otherwise} \end{cases}$$

---

**PFAE's Separation of Duties (Embedded Controls)**

AI recommends
Financial reviews
Management executes

No single agent can:
Recommend, Approve, Execute

*Safety control model:*
Execution = *f* (AI Agent Recommendations, Human Approval, Policy Checks)
(SOX-style internal control requirements}

---

**PFAE's Closed-loop Learning**

Feedback Loop:

*Feedback from actuals →* ***controlled retraining*** *→ validated release*

Actuals → performance monitoring
Drift detection
Controlled retraining
Validated release

Lifecycle gates:

Observe production outcomes
Retrain in approved closed sandbox
Validate (stat + compliance)
Approve (human signoff)
Release with versioned artifacts

Mathematical Framework that doesn't allow deployment without approvals:

$\theta_{t+1}$ = Approve (Validate (Train ($D_{t+1}$)))

PFAE has a three layer control system:

Prediction Layer – Agents
Constraint Layer – Rules and Controls
Explanation Layer – PBLLM Narratives (purpose built)

---

**PFAE AGENTIC MODELS USE CASES IN PHARMACEUTICAL FINANCE:**

**1. Financial Planning & Analysis (FP&A)**

Capabilities -
Rolling forecasts (monthly → weekly)
Scenario modeling for:

Clinical delays
Regulatory outcomes
Manufacturing disruptions
Driver-based forecasting (patients, sites, dosage, timelines)

Kalman Filters / Bayesian Structural Time Series (a statistical technique used for feature selection, time series forecasting, and inferred casual impact)

*Weekly updates revise beliefs as new trial enrollment, spend, or supply data arrives*

Monte Carlo Simulation (mathematical technique that predicts possible outcomes of uncertain events):

Additional Causal models (not just time-series) outputs

Confidence intervals, not point estimates
"Why this changed" explanations
Simulates $$$+ future cost/revenue paths
Output - forecast distribution

PFAE Agents Mathematical Framework:

$$P(\text{Future} \mid \text{New Data}) \propto P(\text{New Data} \mid \text{Future}) \cdot P(\text{Future})$$

PFAE Scenario Modeling Example –

Clinical delays, regulatory outcomes, manufacturing disruptions

PFAE Agents Mathematical Framework –

Bayesian Networks (Causal Graphs):

Nodes - trial success to regulatory approval to launch timing to revenue

Edges encode causal dependencies (not correlations)

Event-driven Monte Carlo:

Random variables:
Trial delay ~ LogNormal (μ, σ)
Approval probability ~ Beta (α, β)
Manufacturing yield ~ Beta distribution

Decision Trees + Real Options:

Value of delaying Phase III of a trial
Value of adding backup CMOs
Expected Value of Information (EVI)

$$EV = \sum_{i=1}^{i} P(\text{scenario}_i) \cdot NPV_i$$

Ex. *Regulatory delay risk at the FDA contributes $47M downside at site P90*

PFAE Driver-Based Forecasting –

(Patients, sites, dosage, timelines)

Structural equation models:

$$\text{Revenue} = \text{Patients} \times \text{Adherence} \times \text{Dose} \times \text{Price}$$
$$\text{Cost} = \text{Sites} \times \text{AvgCostPerSite} + \text{Dose} \times \text{ManufacturingCost}$$

Mathematical Framework -

Hierarchical Bayesian models

Patient enrollment rates vary by:
- Country
- Trial phase
- Site maturity
- Pool data across programs without overfitting

Causal ML (Double ML / Bayesian Causal Forests)
Estimate:
- Effect of adding sites on enrollment speed
- Effect of protocol changes on dropout rate

EX: *Adding 5 EU sites increases Phase II speed by +19% (CI: 11–26%)*
PFAE Forecasts update automatically when drivers change

Change Explanations
Shapley values (the average of all the marginal contributions to all possible coalitions. Computation time increases exponentially with the number of features/variables)

Attribute forecast changes to drivers:
- Patient enrollment
- FX rates
- API cost inflation
- Trial delays

Causal attribution
Separate:
- Ex. What changed because demand fell
  - vs. what changed because manufacturing slipped

Decomposition:
$\Delta Forecast = \Delta Enrollment + \Delta Timelines + \Delta Costs + \Delta FX$

Ex: If the Forecast dropped $21M:
- $9M loss from slower enrollment
- $7M loss from supplier delays
- $5M loss from FX complications

PFAE moves FP&A from budgeting to risk-aware decision modeling. Every forecast includes confidence intervals, causal drivers, and scenario-tested outcomes.

**2. Clinical Trial Financial Management**

Capabilities:
- Study budget forecasting & burn-rate prediction
- Site payment anomaly detection

Accrual accuracy improvement
Change-order impact analysis

Bayesian state-space models (weekly rolling burn)
Tracks spend velocity as hidden state
Updates with:
enrollment events
site activations
protocol amendments
milestone completions

$$Burnt = Burn_{t-1} + \beta 1 \cdot \Delta Sites + \beta 2 \cdot \Delta Patients + \epsilon t$$

Monte Carlo simulation (budget risk)
Simulate:
patient accrual uncertainty
screen failure rates
site startup delays
protocol amendment probabilities
Output - distribution of total study cost, not a single forecast

PFAE Techniques -
Graph models (study ↔ site ↔ vendor ↔ country)
Anomaly detection on invoices & milestones
Controls -
Agentic flags → finance approves → payments released
Full audit trail per recommendation

Site Payment Anomaly Detection
(Invoices, milestones, patient visit claims)

Graph-based anomaly detection
Graph: Study ↔ Site ↔ Vendor ↔ Country
Detect:
unusually dense billing paths
repeated high-cost edges
abnormal invoice patterns per region

Statistical outlier detection:
Isolation Forest
Robust z-scores
Seasonal baselines (sites bill in cycles)

Invoice consistency constraints:
Invoice Amount ≤ Contract Rate × Verified Visits
Accrual Accuracy Improvement
(Patients enrolled vs forecasted)

Hierarchical Bayesian accrual models
Enrollment rate varies by:
country
site maturity
disease area
Partial pooling prevents overreacting to noisy sites

Mathematical Framework –
$EnrollRate_{site} \sim N(\mu_{country}, \sigma_{country})$

Survival / hazard models -
Time-to-next-enrollment per site
Dropout hazard modeling

Causal uplift modeling -
Estimate effect of:
adding clinical study sites
opening new countries
increasing patient stipends

Ex: *Opening 8 LATAM sites expected to reduce time-to-full-enrollment by 14% (CI: 9–19%). Accrual PFAE forecast updates weekly with uncertainty bands.*

Change-Order Impact Analysis –
*(Protocol amendments, CRO scope changes, vendor renegotiations)*

Mathematical Framework:
Causal graph modeling
Protocol change → site workload → monitoring visits → CRO cost → trial duration

Bayesian regression:
$\Delta Cost = f(\Delta Visits, \Delta DataPoints, \Delta Sites, \Delta Duration)$

PFAE Controls: Finance-in-the-Loop (SOX/GxP Friendly)
Human-in-the-loop gating

*AI Flag ⇒ Finance Review ⇒ Payment Release*

Threshold decision rules
Auto-approve if:
anomaly score $< \tau$
Mandatory review if:
anomaly score $\geq \tau$
or change-order impact > $X

PFAE uses probabilistic and causal agents to forecast trial burn, detect billing leakage, and simulate protocol changes with finance approval and full auditability before any dollar moves.

---

**PFAE AGENTIC MODELS APPLICATIONS IN GTN, SPEND INTELLIGENCE, PROCUREMENT AND ADDITIONAL CONTROLS:**

**Revenue, Pricing & Gross-to-Net (GTN)**

Gross-to-Net (GTN) Forecasting:
Net Revenue = List Price − Contracted Rebates – Chargebacks – Coupons/Co-pay Assist – Returns − Prompt Pay Discounts

PFAE Predictive GTN Adjustment (by product × payer × region):

$GTN_{t+1} = f$ (Payer Mix, WAC, Contract Terms, Seasonality, Utilization, Policy Changes)

Capabilities
- Predictive GTN adjustments
- Rebate & chargeback forecasting
- Price elasticity modeling (by payer & geography)

Regulatory Guardrails
- Locked pricing rules
- Explainable models for compliance review

PFAE Rebate & Chargeback Forecasting:

$$\text{Expected Rebates} = \sum_{payers} (Volume_{payer} \times Rebate\_Rate_{payer})$$

$$\text{Chargebacks} = \sum_{\text{channels}} (\text{Units}_{340B/IDN} \times (\text{WAC} - \text{ContractPrice}))$$

Model output produces:
- Forecast accuracy by payer
- Rebate accrual error (%)
- Chargeback leakage rate

Additional Price Fluctuation Modeling:

$$\text{Price Elasticity}_{payer,geo} = \frac{\%\Delta Volume}{\%\Delta Price}$$

Ex. *Price increases 3% in commercial plans in the Midwest, what happens to net revenue vs. volume?*

GTN Audit trail schema
- Inputs used
- Model version hash
- Feature values

Explanation (Shapley-style attribution)
Human approver ID + timestamp

Every payment has a:
- model score
- explanation
- human approval record

(This passes SOX, internal audit, and inspector scrutiny)

**Spend Intelligence & Procurement Finance**

Capabilities (CFO Outcomes):
- Vendor consolidation recommendations
- Maverick spend detection
- Contract leakage identification

Vendor Consolidation:

$$\text{Savings Opportunity} = (\text{Avg Price}_{high-costvendors} - \text{Avg Price}_{low-costvendors}) \times \text{Volume}$$

PFAE agent groups (clusters) vendors by:
- SKU overlap
- Pricing similarity
- Contract terms
- Delivery SLAs

Outlier Spend Detection:

$$\text{Outlier Spend Rate} = \frac{\text{Off-Contract Spend}}{\text{Total Spend}}$$

PFAE agent(s) flags patterns such as:
- PO issued outside approved vendor list
- Invoices missing contract IDs
- Repeated “one-time vendors”

Contract Losses

$$\text{Leakage} = \sum (\text{Contract Price} - \text{Invoice Price}) \times \textit{Units}$$

PFAE Agents NLP on Contracts + Invoices (Enterprise)

Extract:
- Price tiers
- Volume commitments
- Rebate clauses
- Penalties

PFAE Similarity Analysis:
- Detect redundant vendors
- Identify shadow suppliers
- Flag unusual pricing patterns

---

**PFAE Pharmaceutical Patent Management**

Patent Value Scoring

PFAE Agent ingests:
- Patent scope & claims strength
- Market size by geography
- Competitive landscape
- Probability of challenge/invalidation
- Time to expiry

Output: Patent ROI score to guide:
- Filing
- Maintenance
- Legal defense spending

*Single score to guide whether to file, maintain, or aggressively defend*

Inputs (normalized 0–1):
- Claims Strength (CS) – NLP + legal precedent similarity
- Patent Scope Breadth (SB) – number of enforceable claim vectors
- Market Size by Geo (MS) – Σ (market × probability of protection × margin)
- Competitive Density (CD) – inverse weight (more competitors = lower score)
- Challenge Risk (CR) – predicted invalidation probability
- Time to Expiry (TE) – discounted value curve

$$\text{Patent ROI Score} = (\alpha CS + \beta SB + \gamma MS + \delta(1-CD)) \times (1- CR) \times D(TE) - \text{Expected Legal Cost}$$

Whereby:

$$D(TE) = e^{-r \cdot (TE)}$$

Output: 0–100 score

Decision thresholds:
- >75 → File + Defend aggressively
- 40–75 → Maintain selectively

<40 → Let expire / don't file

Level of Evidence (LOE) Impact Prediction

PFAE Predicts:

Generic entry timing
Speed of revenue erosion
Price compression curves
Channel mix shifts post - LOE

Output: Scenario-adjusted revenue forecasts used in FP&A and guidance

Royalty & Licensing Intelligence

PFAE reads contracts (NLP) and:

Extracts royalty terms
Flags inconsistencies
Simulates under-/over-payment risk
Predicts future royalty streams

Output: Automated royalty validation + leakage detection

Litigation & Patent Challenge Risk Modeling

PFAE Predicts:

Likelihood of ANDA challenges
Litigation duration
Settlement vs trial outcomes
Financial downside scenarios

Output: Probabilistic legal reserve modeling for finance prediction

PFAE Full Architecture

Inputs:

Patent databases (USPTO, EPO, WIPO)
IP management systems
ERP / Finance systems
Contract lifecycle management (CLM)
Sales, GTN, market access data
Litigation history & outcomes
Competitive intelligence

Processing Layer:

NLP for patent claims & contracts
Graph AI linking patents to products to revenue
Time-series forecasting models
Monte Carlo simulations for risk

Outputs:
- Finance dashboards
- FP&A forecast feeds
- Board-level risk views
- Automated alerts (LOE, litigation risk, royalty leakage)

*Overall Governance, Controls & Validation (Regulator-safe)*

PFAE Governance**:**
- Human-in-the-loop for material decisions
- Agentic approval committee (Finance + Legal + IP + Risk)
- Explainability requirements for forecasts impacting guidance
- Audit trails on model outputs used in financials

Validation Controls:
- Back-testing vs actual LOE outcomes
- Bias testing on litigation predictions
- Agentic drift monitoring
- Independent validation (2nd line of defense)
- Scenario approval workflows

Compliance:
- SOX controls over PFAE generated forecasts
- Disclosure controls for material IP risks
- Transfer pricing documentation support
- Data privacy & security controls

---

**Controls & CFO Guardrails**

Every PFAE recommendation must show:
- Contract clause source
- Invoice line evidence
- Historical benchmark

Audit-Ready and Finance Friendly KPIs:
- % spend on preferred vendors
- Outlier spend reduction *QoQ*
- Verified savings vs. theoretical savings

Value Function:

$V = \alpha$ (Accuracy) + $\beta$ (Speed) + $\gamma$ (Loss Captured)

Trust Function:

$$T = \frac{\text{PFAE Accepted Recommendations}}{\text{Total recommendation}}$$

CFOs care about V

Auditors care about T

---

**PFAE Financial Closed & Controls Automation**

Capabilities :

- AI-Assisted Close Checklist
- Predict likely late close tasks
- Risk-score reconciliations
- Flag unusual account volatility

Journal Entry Suggestions (Low Risk Only)

Examples allowed:

- Accrual true-ups
- FX remeasurement
- Reclassifications

$JE_{suggested} = f$ (Historical Patterns, Seasonality, Variance Signals)

Variance Explanation Narratives (NLG)

Ex. *COGS increased 6.2% primarily due to raw material inflation, volume mix shift to lower-margin SKUs (+1.7%), and freight surcharges (+0.7%).*

PFAE Agent Techniques:

Rules + ML Agent Hybrid

- Rules define allowed actions
- ML Agent detects anomalies and patterns
- Hard stop if outside risk band

Natural Language Generation (NLG)

- CFO-ready narratives
- Audit-friendly traceability and explainable

---

PFAE Audit Friendly (and SOX)

No Auto-Posting:

- AI can propose
- Humans approve
- System logs everything

*SOX Mapping per AI Action*

| PFAE Action | SOX Control |
|---|---|
| GTN forecast | Management review control |
| Journal suggestion | Dual approval + threshold rules |
| Variance explanation | Disclosure control |
| Spend recommendation | Procurement policy control |

Audit KPIs

- % of PFAE suggested entries rejected
- % close tasks accelerated
- Post-close adjustment rate outcome

CFO-visible savings with auditable evidence

---

PFAE Reference Architecture




Key Design Choices:

- PFAE never writes directly to ERP
- Read-only ingestion
- Human-in-the-loop enforced at workflow level

**Governance & Validation Model**

PFAE Validation Tiers:

| Tier | Use Case | Validation Level |
|---|---|---|
| Tier 1 | Narrative insights | Low |
| Tier 2 | Forecasts & recommendations | Medium |
| Tier 3 | Financial impact decisions | High (IQ/OQ/PQ) |

Model Risk Management:

- Versioned models
- Locked training datasets
- Bias & drift monitoring
- Kill-switch per model